Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

NAD · NANOPARTICLES FOR THERAPY AND DIAGNOSIS OF ALZHEIMER DISEASE

FP7Status: CLOSED1 September 200831 August 2013EU funding €10,921,350

The search for effective therapies and early detection strategies for Alzheimer’s Disease (AD), the major cause of dementia in Europe, is imperative. It is known that β-amyloid (Aβ) peptide plays a central role in neurodegeneration. In AD brain, Aβ is released in a soluble form that progressively becomes insoluble forming aggregates; extracellular plaques mainly composed of Aβ are a hallmark of post-mortem brains. These premises strongly suggest brain Aβ as a possible target for therapy and diagnosis of AD. In addition, it is known that brain and blood Aβ pools are in equilibrium via the blood-brain-barrier (BBB). Accordingly, it has been reported that removal of blood Aβ may withdraw the excess of brain Aβ by a “sink” effect. Thus, blood Aβ is another potential target. The aim of this project is to utilize nanoparticles (NPs) specifically engineered for targeting brain Aβ, for the combined diagnosis and therapy (theranostics) of AD. NPs (liposomes, solid lipid NPs, polymeric-NPs) will be multiple-functionalized with: i) a large arsenal of molecules (specific lipids, antiamyloidogenic drugs, polyphenols, heteroaromatic compounds, unnatural peptides and peptidomimetics, antibodies) interacting with Aβ in all aggregation forms, ii) PET or MRI contrast agents detecting such interaction, iii) molecules stimulating BBB crossing via the transcytotic route. Several artificial and cellular models will be used to fine-tune such features and to improve NPs biocompatibility, non-immunogenicity, non-toxicity and physical stability. Eventually, absorption, distribution, metabolism and excretion will be studied using animal models of AD. Different routes (i.v., oral, nasal) and protocols (two-step, NPs cocktails, aerosols) of administration will be utilized to boost NPs brain delivery. The prediction is that NPs will detect, disaggregate and remove Aβ brain deposits. In any case, NPs will interact with blood Aβ, withdrawing the excess of brain peptide by a “sink” effect.

Consortium · 19 organisations

coordinator

UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA

IT · €2,930,387

participant

UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6

FR · €102,593

participant

UNIVERSITEIT ANTWERPEN

BE · €584,920

participant

STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA

PT · €208,920

participant

BIAL INDUSTRIAL FARMACEUTICA S.A.

ES · €105,200

participant

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

IT · €674,000

participant

UNIVERSITE PARIS-SUD

FR · €879,901

participant

KOBENHAVNS UNIVERSITET

DK · €409,882

participant

GUERBET SA

FR · €100,004

participant

BIOTALENTUM TUDASFEJLESZTO KFT

HU · €499,600

participant

UNIVERSITY OF LANCASTER

UK · €314,378

participant

KAROLINSKA INSTITUTET

SE · €455,486

participant

CENTRO DE INVESTIGACION BIOMEDICA EN RED ENFERMEDADES NEURODEGENERATIVAS

ES · €707,513

participant

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

NL · €305,308

participant

UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA

ES · €261,000

participant

TURUN YLIOPISTO

FI · €919,858

participant

PANEPISTIMIO PATRON

EL · €784,520

participant

NANOVECTOR SRL

IT · €487,976

participant

CHEMICKY USTAV SLOVENSKEJ AKADEMIEVIED

SK · €189,904

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.